• Context Therapeutics dosed the first patient in a Phase 1 trial of CT-202, a Nectin-4 x CD3 bispecific antibody for solid tumors.
• The study is testing CT-202 as a monotherapy in refractory or resistant Nectin-4-expressing cancers, including urothelial, colorectal, and triple-negative breast cancer.
• No clinical results have been presented; initial Phase 1a data are expected in the second half of 2027.
• The trial aims to assess safety and tolerability, gauge drug behavior in the body, and look for early signs of anti-tumor activity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090730PRIMZONEFULLFEED9823404) on September 09, 2026, and is solely responsible for the information contained therein.